TGIF. I’m Rachana Pradhan, a correspondent for KFF Health News. Send tips and your favorite holiday cookie recipes to rachanap@kff.org. Not a subscriber? Sign up here.
Today’s edition: Congress is skipping town with a federal financing deadline looming in the new year. Federal regulators are urging health care providers to help boost lagging immunizations. But first …
Even patient advocacy groups collect drug company dollars
Pharma money is all over the place — in universities, companies doing continuing medical education for doctors and in prominent patient advocacy organizations that are household names across America.
Public Citizen, a consumer advocacy nonprofit, reports today that between 2010 and 2022, the drug industry’s main lobbying group and member companies provided at least $6 billion in grants to more than 20,000 organizations. The analysis, provided exclusively to KFF Health News in advance of its release, focused on the Pharmaceutical Research and Manufacturers of America (PhRMA) and 31 drug companies that were members of the trade group as of March.
The money dwarfs industry spending over that time on federal lobbying and campaign contributions to lawmakers. With high drug prices a regular topic of debate in Washington, drug industry grants to patient advocacy groups in particular raises questions about conflicts of interest — including whether organizations that accept the industry’s money shy away from pushing policies the drugmakers oppose, even if patients may benefit.
“There’s a risk that those entanglements influence the work of those organizations,” said Matthew McCoy, an assistant professor of medical ethics and health policy at the University of Pennsylvania who has studied patient advocacy groups’ influence and transparency.
He said there’s another important dynamic likely at play, too. Companies aren’t blindly choosing which groups to fund but instead are “probably selecting organizations that are already inclined to see the world, see the policy issues, the way they see it.”
A couple examples you’ll recognize: The American Heart Association received $64.1 million over the 12-year period. The American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network, together received $23.1 million.
The question is whether the money affects the heavyweight groups’ advocacy. After the House passed the Inflation Reduction Act in August 2022, the American Cancer Society Cancer Action Network’s statement hailed the bill’s cap on Medicare enrollees’ out-of-pocket costs for prescription drugs and additional tax credits for ACA insurance plans. But the group was silent on a contentious provision giving Medicare the ability to negotiate drug prices with manufacturers.
Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said in an emailed statement that the organization didn’t take a formal position on Medicare drug negotiation because “the policy’s impact on patient access to and affordability of cancer treatments was unclear.” In contrast, the Part D out-of-pocket cap “has evidence-based patient benefit.”
- “ACS CAN’s only constituents are cancer patients, survivors, and their loved ones nationwide. ACS CAN’s policy agenda is driven entirely by evidence with the single purpose of achieving our mission to end cancer as we know it, for everyone,” she added. “Contributions to the organization do not influence policy decisions or positions.”
The American Heart Association similarly has touted its support of the three-year extension of enhanced Obamacare tax credits in the IRA, but was silent on drug price negotiation. “We have strict standards in place to monitor relationships with industry and protect against conflicts of interest,” Steve Weiss, a spokesperson for the group, said in an emailed statement. “These funds in no way influence our advocacy, programs or science.”
- “We engage with different organizations who have a wide array of health care opinions and priorities,” Alex Schriver, senior vice president of public affairs at PhRMA, said in an emailed statement. “We may not agree on every issue, but we believe engagement and dialogue is important to promoting a health care policy environment that supports innovation, a highly-skilled workforce and access to lifesaving medicines.”
While the patient groups’ primary mission is to advocate for people with particular diseases, including by boosting funding for research, their work in Washington often bolsters that of pharmaceutical companies whose drugs their patients rely upon. At the same time, the story isn’t always black and white, and just because a group gets money doesn’t automatically make them a “pharma lackey,” said Mike Tanglis, research director at Public Citizen. “It’s not so clean cut,” McCoy added.
The American Diabetes Association received $26.4 million from the drug industry — yet the group supported allowing Medicare to negotiate prescription drug prices. Multiple drug companies have sued to stop the program.
Francisco Prieto, chair of the American Diabetes Association’s national advocacy committee, said in a statement that support from its corporate and other partners allows the group to provide resources about diabetes to health care personnel as well as patients and their caregivers.
“Our partners do not influence our business or policy decisions, which are made solely based on our mission and what is in the best interest of patients around the world,” he said.
Many groups receiving grants do criticize high drug prices generally or highlight patients’ difficulties in affording care. But, “specifically calling out pharma companies doesn’t seem to be a huge priority for them,” Tanglis said.
It isn’t always obvious which groups drug companies are paying. Congress in 2010 enacted the Physician Payments Sunshine Act, a law that required payments to physicians from drug and medical device makers to be registered on a public website. But patient groups were not addressed in the bill. Drug companies’ payments to patient groups can be — but aren't always — included in annual filings to the IRS or in charitable giving reports.
The American Heart Association in its 2022 annual report lists contributions from corporations, foundations and others. The American Diabetes Association in its latest annual report lists corporate sponsors and ranges for the amounts they give, but not precise dollar figures. Similarly, the American Cancer Society’s most recent report names corporate sponsors giving more than $1 million, but exact amounts aren’t disclosed.
McCoy believes there should be “some kind of mandated transparency across the board” for payments and that patient groups should openly answer questions about steps they take to make sure the funding doesn’t influence their decisions.
“Those are all great things that patient advocacy groups can and should be doing,” McCoy said.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — an independent source of health policy research, polling and journalism.
Agency alert
CDC urges providers to boost vaccination rates
The Centers for Disease Control and Prevention is warning health care providers that there is an “urgent need” to ramp up immunization coverage against influenza, covid-19 and respiratory syncytial virus (RSV).
Lagging vaccination rates, coupled with rising viral activity across the country, could lead to more severe disease and further strain the U.S. health care system in the coming weeks, the agency said in an alert.
The push by health regulators to boost immunizations coincides with an ongoing effort to ease national shortages of a newly approved drug designed to protect infants against RSV. The White House announced yesterday that the shot’s manufacturers, Sanofi and AstraZeneca, will deliver an additional 230,000 doses in January.
Meanwhile …
U.S. agents recently confiscated more than $18 million worth of unauthorized e-cigarettes from overseas manufacturers, the Biden administration announced yesterday.
The details: Officials intercepted the shipments in July, seizing about 1.4 million units at Los Angeles International Airport in a joint three-day operation between the Food and Drug Administration and Customs and Border Protection. Many of the shipments were internationally mislabeled as toys, shoes and other items in an effort to evade detection, the agencies said.
- Among the manufacturers with products involved is iMiracle Shenzhen, the Chinese firm behind Elf Bar, a line of cheap, disposable vapes popular among young e-cigarette users. The company didn’t immediately respond to a request for comment.
FDA Commissioner Robert Califf:
On the Hill
- On our radar: Congress passed a two-part continuing resolution in November that funds some government agencies and programs at their current levels until Jan. 19, including federally-backed community health centers, teaching hospitals and special diabetes initiatives. The remaining government funding — covering the Department of Health and Human Services, among others — expires on Feb. 2.
- The House passed the annual defense authorization bill yesterday, delivering bipartisan rebuke to a group of hard-line Republicans that sought to use the legislation as a vehicle to restrict access to abortion and gender-affirming care for service members and dependents, The Post’s Abigail Hauslohner reports.
- House Republicans threatened the Food and Drug Administration with a subpoena, saying the agency allegedly failed to respond to its requests for information on foreign drug inspections, according to a letter sent to Commissioner Robert Califf yesterday.
Quote of the week
“She’s not the first person I’ve talked to in the middle of an emergency ... She’s just the first person who filed a lawsuit.”— Molly Duane, a lawyer at the Center for Reproductive Rights who represented Kate Cox in her effort to legally terminate her pregnancy in Texas under the state’s abortion bans.
Health reads
Sugar rush
The Post dropped its second annual Newsprint this week. Learn about your reading habits with us in 2023, including your favorite authors, stories and topics, here.
The Washington Post’s Newsprint launches this December with new features.
Back by popular demand, Newsprint enters its second year with video messages from over 100 journalists, an immersive quiz, and morehttps://t.co/u2Wj1qA4RT
— Washington Post PR (@WashPostPR) December 11, 2023
"flow" - Google News
December 15, 2023 at 10:35PM
https://ift.tt/zNCHoB2
Analysis | Millions of dollars flow from pharma to patient advocacy groups - The Washington Post
"flow" - Google News
https://ift.tt/dnxlV3K
https://ift.tt/zMAJCvZ
Bagikan Berita Ini
0 Response to "Analysis | Millions of dollars flow from pharma to patient advocacy groups - The Washington Post"
Post a Comment